BPC-157 Dosage Protocol

In short: BPC-157 has 200+ animal studies, zero completed human efficacy trials, and a research-chem-only supply chain — the gap between hype and evidence is enormous.

Body Protection Compound 157 (BPC-157) is a synthetic 15-amino-acid fragment (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a cytoprotective protein isolated in human gastric juice by the Sikiric laboratory at the University of Zagreb [1]. The compound has accumulated more than two hundred preclinical publications describing tissue-repair activity in tendon, ligament, gut mucosa, bone, and nerve models, with zero completed human efficacy trials as of early 2026 [2]. Reported protocols cluster around 10 micrograms per kilogram daily in rodent studies and 250 to 500 micrograms once or twice daily via subcutaneous injection in community self-report data, with oral administration typically reserved for gastrointestinal indications [1,3].

How BPC-157 Works: Mechanism of Action

In short: BPC-157 seems to work through angiogenesis and nitric oxide signaling at injury sites — but nearly all the evidence comes from one research group, and there's no human pharmacokinetic data.

BPC-157 does not appear to act through a single receptor. Published mechanistic work implicates vascular endothelial growth factor receptor 2 (VEGFR2) upregulation, nitric oxide synthase modulation, and activation of the focal-adhesion-kinase paxillin pathway that governs cell migration and tissue remodeling [2,4]. Sikiric and colleagues have proposed that BPC-157 functions as a pleiotropic cytoprotective agent, with its most consistently reproducible effects centered on angiogenesis and endothelial tubulogenesis at sites of injury [2]. In Achilles tendon transection models in rats, intraperitoneal and local BPC-157 administration produced measurable increases in tensile strength and collagen organization at two and four weeks post-injury [3].

Pharmacokinetic characterization of BPC-157 in humans is absent. Rodent data suggest a short plasma half-life estimated at less than thirty minutes following intraperitoneal injection, with the peptide nonetheless producing sustained biological effects attributed to downstream signaling cascades rather than prolonged circulating concentrations [2]. Oral bioavailability has been reported in rat intragastric studies, with the compound appearing sufficiently stable in gastric acid to exert local mucosal effects and, according to some authors, gut-mediated systemic signaling [5]. Independent pharmacokinetic replication outside the Zagreb group is limited.

The nitric oxide axis is a second mechanistic node. BPC-157 has counteracted both L-NAME-induced NO deficiency and L-arginine-induced NO excess in rodent cardiovascular and gastric models, suggesting bidirectional normalization rather than simple agonism [4]. The compound has also demonstrated interactions with the serotonergic and dopaminergic systems in behavioral models, though these findings have not been independently replicated at scale.

A key caveat: the majority of the published BPC-157 literature originates from a single research group. Scientific confidence in reported effect sizes is therefore lower than the raw publication count would suggest, and translation to human dose-response remains uncharacterized [2,6]. Independent replication is available for specific endpoints, including tendon outgrowth in vitro and colon anastomosis healing in rats, though meta-analytic synthesis across laboratories is not yet feasible given methodological heterogeneity [6,8,9].

The compound has also been characterized in the published record as "stable" in gastric acid relative to comparable short peptides, with acid-stability claims grounded in observed oral activity in rat gastric, duodenal, and colonic injury models rather than in direct degradation-kinetics measurements [1,5]. This distinction matters for dose interpretation: what the literature documents is preserved biological activity after oral delivery, not a measured oral bioavailability percentage comparable to pharmaceutical standards.

BPC-157 Dose Ranges in the Peer-Reviewed Literature

In short: rodent studies use ~10 µg/kg daily; community self-report protocols run 250–500 µg once or twice daily subcutaneously — and no human trial has ever validated the translation between the two.

Dose reporting varies by route and indication. The table below reflects published primary literature and commonly documented community self-report protocols.

The preclinical range spans approximately three orders of magnitude depending on indication and route. Applying standard allometric body-surface-area scaling from a rat dose of 10 micrograms per kilogram to a seventy-kilogram adult yields a projected human-equivalent dose near 110 micrograms total, which sits below the 250 to 500 microgram ranges typically described in community protocols [2]. No human dose-finding study has validated this translation.

BPC-157 Reconstitution: Math and Worked Examples

In short: the math is simple — concentration equals mass divided by volume — but it only holds if the vial actually contains the mass on the label.

BPC-157 is typically supplied as a lyophilized powder in 5 mg or 10 mg glass vials requiring reconstitution with bacteriostatic water (BAC water) prior to subcutaneous injection.

Concentration formula: Concentration (mg/mL) = Vial mass (mg) ÷ Diluent volume (mL)

Worked example — 5 mg vial:

• Vial: 5 mg BPC-157
• BAC water added: 2 mL
• Resulting concentration: 2.5 mg/mL (2,500 µg/mL)
• For a 250 µg dose: 0.25 mg ÷ 2.5 mg/mL = 0.1 mL = 10 units on a U-100 insulin syringe
• For a 500 µg dose: 0.5 mg ÷ 2.5 mg/mL = 0.2 mL = 20 units on a U-100 insulin syringe

Worked example — 10 mg vial:

• Vial: 10 mg BPC-157
• BAC water added: 2 mL
• Resulting concentration: 5 mg/mL (5,000 µg/mL)
• For a 250 µg dose: 0.25 mg ÷ 5 mg/mL = 0.05 mL = 5 units on a U-100 insulin syringe
• For a 500 µg dose: 0.5 mg ÷ 5 mg/mL = 0.1 mL = 10 units on a U-100 insulin syringe

Reconstitution accuracy depends directly on labeled vial mass. Published third-party lab reports across the BPC-157 vendor landscape have documented quantity deviations exceeding plus or minus 80 percent on some labels, which means the mathematical conversions above hold only when the vial actually contains the mass stated on the label.

How BPC-157 Is Administered

In short: subcutaneous injection near the injury site is the most-described route in community protocols; oral is reserved for gut indications; topical and intramuscular are rare.

Subcutaneous injection is the most frequently described route in community and clinician-reported protocols, typically delivered into the abdominal fat pad or into subcutaneous tissue as close to the injured site as anatomically practical [6]. The near-site rationale rests on the hypothesis that local concentration at the repair site is mechanistically relevant, although no controlled human data confirms that near-site injection outperforms distal subcutaneous administration.

Injection site rotation is recommended to reduce localized irritation. Insulin syringes with 29- to 31-gauge needles of 5/16-inch to 1/2-inch length are standard for subcutaneous delivery. The vial should be stored refrigerated after reconstitution, with most literature suggesting that BPC-157 retains activity for approximately 30 days at 2 to 8 degrees Celsius in BAC water.

Oral administration is reported for gastrointestinal indications, with the rodent data suggesting the peptide retains sufficient acid stability to exert local mucosal effects [5]. Capsule and sublingual liquid formulations are both described. For systemic musculoskeletal targets, oral bioavailability is considered by most commentators to be too low to replicate the exposures achieved by injection, though this has not been formally quantified in humans.

Intramuscular injection is occasionally described in older case reports but is not well represented in the preclinical record. Topical application has been studied in rodent skin-wound models but is uncommon in community protocols.

Timing relative to meals has not been established in the literature. Timing relative to training is similarly uncharacterized. No pharmacokinetic justification exists for fasted versus fed administration, and published rodent studies have delivered BPC-157 under both fed and fasted conditions without a reported effect-size differential.

Storage practice reported in clinician and community sources treats lyophilized BPC-157 as stable at 2 to 8 degrees Celsius for the labeled shelf life. Once reconstituted in bacteriostatic water, the prevailing convention is 30 days at refrigerated temperature, though no peer-reviewed stability assay publicly validates that specific duration. Freeze-thaw cycles are generally avoided.

BPC-157 Cycle Structure and Protocol Duration

In short: the 4-weeks-on / 4-weeks-off convention is pragmatic folklore, not evidence. No human duration-response data exists.

Reported cycle lengths in the preclinical literature typically span two to four weeks at daily administration, paralleling the timeframes at which tissue-repair endpoints are measured in rodent studies [3,7]. Community and clinician-reported protocols commonly describe four- to twelve-week cycles followed by a washout period of several weeks before re-initiation.

No dose-response or duration-response data exists in humans. No published tolerance or desensitization data is available from either preclinical or clinical sources. The concept of cycling BPC-157 is rooted in general peptide practice rather than compound-specific evidence; there is no mechanistic reason identified in the literature that would require cycling, and equally no long-duration safety data that would support continuous use. Clinician-reported protocols frequently adopt a four-week-on, four-week-off structure as a pragmatic default, explicitly described in published case-series commentary as conservative rather than evidence-based.

Long-term administration concerns focus on the pro-angiogenic mechanism and the theoretical possibility of promoting growth of undiagnosed lesions with angiogenic dependence. No long-term carcinogenicity studies have been completed.

BPC-157 Side Effects and Safety Profile

In short: no controlled human safety trial exists. Community-reported side effects are mostly mild; the real concern is pro-angiogenic activity in anyone with undiagnosed tumors and contaminants from low-quality vendors.

No controlled human clinical trial has quantified BPC-157 side-effect frequency. Anecdotal and clinician-reported adverse events include transient nausea (more common with oral administration), lightheadedness, headache, injection-site erythema and induration, blood pressure fluctuations in both directions, and fatigue [6].

Preclinical toxicology in rats has not identified acute or subchronic toxicity at doses substantially higher than those used in efficacy studies, but long-duration and carcinogenicity studies are absent [2].

Contraindications most frequently cited in clinician commentary include active or prior malignancy, given BPC-157's established pro-angiogenic mechanism; pregnancy and lactation due to absent reproductive data; and concurrent use of anti-angiogenic oncology therapies such as bevacizumab, where mechanistic antagonism is plausible.

Theoretical drug interactions include potentiation or attenuation of antihypertensive agents via nitric oxide modulation, interaction with dopaminergic agents including L-DOPA and antipsychotics, and interaction with anticoagulants given vascular effects. None of these interactions have been formally characterized in humans.

BPC-157 is prohibited under the World Anti-Doping Agency (WADA) code for competitive athletes under peptide hormones, growth factors, and related mimetics.

Quality-related adverse events are a separate category and are a function of the vendor rather than the molecule. Published third-party lab reports across the BPC-157 research-chemical market have documented contaminant peaks on HPLC chromatograms and truncated sequence impurities on mass-spectrometry traces, and any of these could produce an adverse reaction that would be mistakenly attributed to BPC-157 itself. For this reason, editorial protocols in clinician publications consistently emphasize sourcing from vendors publishing third-party certificates of analysis.

BPC-157 Vendor Ratings: Who Publishes Lab Data at ≥99% Purity?

Which BPC-157 vendors publish lab data at or above 99% purity?

TriedRx compiles publicly available third-party HPLC and mass-spectrometry reports, vendor transparency disclosures, regulatory actions, and reputation data — then grades each vendor on a transparent rubric. Because quantity accuracy is where BPC-157 vendors most frequently fail, our rankings weight both HPLC purity and quantitative mass assay results rather than purity alone. We do not accept vendor payments, do not run affiliate links on research content, and do not run our own chromatography — every data point in a vendor grade comes from a lab report we can cite.

See all vendors tested for BPC-157 → /brands?peptide=bpc-157

Related: BPC-157 Research Profile and Vendor Rankings

In short: if you came for a dosing chart, these are the next pages that add context — evidence base, safety debates, and the related arginate analog.

For a full research background covering the BPC-157 evidence base, the angiogenesis-cancer safety discussion, the oral-versus-injection debate, and aggregated third-party vendor quality data, see the TriedRx BPC-157 peptide profile. Readers considering the widely discussed BPC-157 plus TB-500 combination protocol should also review the TB-500 dosing protocol and the TriedRx pentadeca arginate profile, a related BPC-157 analog with purported stability advantages.

References

1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. PMID: 21548867.
2. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 22026995.
3. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 20388954.
4. Sikiric P, Seiwerth S, Brcic L, et al. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2010;16(10):1224-1234. PMID: 20388117.
5. Veljaca M, Pavic-Sladoljev D, Mildner B, et al. Safety, tolerability, and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis. Gastroenterology. 2003;124(4 Suppl 1):A-241. ClinicalTrials.gov NCT02637284.
6. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID: 21212190.
7. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. PMID: 21832915.
8. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PMID: 31062110.
9. Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. PMID: 33995035.